BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8956800)

  • 1. A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
    Weaver A; Wrigley E; Watson A; Chang J; Collins CD; Jenkins B; Gill C; Pettengell R; Dexter TM; Testa NG; Crowther D
    Br J Cancer; 1996 Dec; 74(11):1821-7. PubMed ID: 8956800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.
    Weaver A; Chang J; Wrigley E; de Wynter E; Woll PJ; Lind M; Jenkins B; Gill C; Wilkinson PM; Pettengell R; Radford JA; Collins CD; Dexter TM; Testa NG; Crowther D
    J Clin Oncol; 1998 Aug; 16(8):2601-12. PubMed ID: 9704709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
    Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
    Demirer T; Rowley S; Buckner CD; Appelbaum FR; Lilleby K; Storb R; Schiffman K; Bensinger WI
    J Clin Oncol; 1995 Jul; 13(7):1714-9. PubMed ID: 7541450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
    Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
    Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
    Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.
    Toner GC; Green M; Bishop JF; McKendrick J; Cebon J; Sheridan WP; Lockbaum P; O'Byrne J; Fox RM
    Am J Clin Oncol; 1998 Jun; 21(3):263-9. PubMed ID: 9626795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
    Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
    J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
    Sheridan WP; Begley CG; Juttner CA; Szer J; To LB; Maher D; McGrath KM; Morstyn G; Fox RM
    Lancet; 1992 Mar; 339(8794):640-4. PubMed ID: 1371817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study.
    Schilder RJ; Brady MF; Spriggs D; Shea T
    Gynecol Oncol; 2003 Jan; 88(1):3-8. PubMed ID: 12504619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
    Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
    Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
    Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.
    Leyvraz S; Ketterer N; Perey L; Bauer J; Vuichard P; Grob JP; Schneider P; von Fliedner V; Lejeune F; Bachmann F
    Br J Cancer; 1995 Jul; 72(1):178-82. PubMed ID: 7541235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer.
    Baumann I; Swindell R; Van Hoeff ME; Dexter TM; de Wynter E; Lange C; Luft T; Howell A; Testa NG
    Ann Oncol; 1996 Dec; 7(10):1051-7. PubMed ID: 9037364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.
    Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.